Sign In
Buy ATRC
$26.20
+0.340 (+1.31%)
At Close: Jun 03, 2026
Will AtriCure (ATRC) Report Negative Earnings Next Week? What You Should Know
11:05am, Wednesday, 05'th Feb 2025
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
08:00am, Wednesday, 22'nd Jan 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 23'rd Dec 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript
11:53pm, Tuesday, 29'th Oct 2024
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer
AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
08:01pm, Tuesday, 29'th Oct 2024
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics comp
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
06:11pm, Tuesday, 29'th Oct 2024
AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago.
AtriCure Reports Third Quarter 2024 Financial Results
04:01pm, Tuesday, 29'th Oct 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-op
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
01:15pm, Wednesday, 16'th Oct 2024
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
08:00am, Tuesday, 15'th Oct 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure Gets CE Mark for EnCompass Clamp, Expands in Europe
11:30am, Friday, 11'th Oct 2024
ATRC's EnCompass Clamp receives a CE Mark, enabling European surgeons to access faster, simpler heart ablation in cardiac surgeries with advanced radiofrequency technology.
AtriCure to Announce Third Quarter 2024 Financial Results
08:00am, Tuesday, 08'th Oct 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
Faisal Al Bannai
07:23am, Thursday, 05'th Sep 2024
In 2023, the Advanced Technology Research Council (ATRC), an arm of the Abu Dhabi government, spent millions of dollars building a series of large language models. ATRC secretary general Faisal Al Ban
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
01:15pm, Wednesday, 28'th Aug 2024
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device
08:00am, Tuesday, 27'th Aug 2024
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-o
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
01:10pm, Friday, 23'rd Aug 2024
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
